TY - JOUR
T1 - Development of vaccines against Zika virus
AU - Poland, Gregory A.
AU - Kennedy, Richard B.
AU - Ovsyannikova, Inna G.
AU - Palacios, Ricardo
AU - Ho, Paulo Lee
AU - Kalil, Jorge
N1 - Funding Information:
We searched PubMed using the following terms “ZIKV“, “Zika“, OR “Zika virus” alone and in combination with “vaccine”, “vaccine development”, “infection”, “pathogenesis”, “outbreak”, “pregnancy”, “birth defect”, OR “animal model”. We searched from inception to Nov 6, 2017. All types of articles were included. We only considered articles published in English. We also searched clinical trial websites (ie, ClinicalTrials.gov ), PubMed, and Google Scholar for press releases about Zika virus products. Contributors GAP, RBK, IGO, RP, PLH, and JK drafted sections of the Review according to their own areas of expertise and their literature searches. Declaration of interests GAP is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories and consultants on vaccine development for Merck & Co, Avianax, Dynavax, Novartis Vaccines and Therapeutics, Adjuvance Technologies, Seqirus, and Protein Sciences. GAP and IGO have three patents related to vaccinia and measles peptide research. RBK has received funding from Merck Research Laboratories to study waning immunity to mumps vaccine. All other authors declare no competing interests. Acknowledgments We thank Caroline L Vitse (Mayo Clinic Vaccine Research Group) for editorial assistance.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/7
Y1 - 2018/7
N2 - Zika virus is an emerging pathogen of substantial public health concern to human beings. Although most infections are asymptomatic or present with benign, self-limited symptoms, a small percentage of patients have complications, such as congenital anomalies in the developing fetus of pregnant women infected with the virus and neurological complications (eg, Guillain-Barré syndrome). To date, there is no vaccine, antiviral drug, or other modality available to prevent or treat Zika virus infection. In this Review, we examine vaccine development efforts for Zika virus to date and research gaps in the development of candidate vaccines against Zika virus. Top research priorities should include development of a better understanding of immunity to Zika virus to establish clear correlates of protection; determination of what effect, if any, Zika vaccine-induced immune responses will have on subsequent dengue virus infection; evaluation of vaccine immunogenicity and efficacy in healthy adults and in the various subpopulations affected by Zika virus infection (children, pregnant women, women of childbearing age, and eldery people); and identification of the molecular mechanisms that underlie birth defects and neurological sequelae related to Zika virus.
AB - Zika virus is an emerging pathogen of substantial public health concern to human beings. Although most infections are asymptomatic or present with benign, self-limited symptoms, a small percentage of patients have complications, such as congenital anomalies in the developing fetus of pregnant women infected with the virus and neurological complications (eg, Guillain-Barré syndrome). To date, there is no vaccine, antiviral drug, or other modality available to prevent or treat Zika virus infection. In this Review, we examine vaccine development efforts for Zika virus to date and research gaps in the development of candidate vaccines against Zika virus. Top research priorities should include development of a better understanding of immunity to Zika virus to establish clear correlates of protection; determination of what effect, if any, Zika vaccine-induced immune responses will have on subsequent dengue virus infection; evaluation of vaccine immunogenicity and efficacy in healthy adults and in the various subpopulations affected by Zika virus infection (children, pregnant women, women of childbearing age, and eldery people); and identification of the molecular mechanisms that underlie birth defects and neurological sequelae related to Zika virus.
UR - http://www.scopus.com/inward/record.url?scp=85041608916&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041608916&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(18)30063-X
DO - 10.1016/S1473-3099(18)30063-X
M3 - Review article
C2 - 29396004
AN - SCOPUS:85041608916
VL - 18
SP - e211-e219
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
SN - 1473-3099
IS - 7
ER -